Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04362072 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | completed | Phase 4 | 71 | PfizerINDUSTRY | 7 | Jun 11, 2025 | clinicaltrials |
| NCT05796245 | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis | completed | — | 2,207 | PfizerINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
| NCT05834348 | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.(DELINOR) | completed | — | 5,279 | PfizerINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05166135 | Latin American Real-world Study in Acute Leukemia(LOYAL) | completed | — | 589 | PfizerINDUSTRY | 4 | Mar 25, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT03269136 | PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | completed | Phase 1 | 101 | PfizerINDUSTRY | 2 | Mar 18, 2025 | clinicaltrials |
| NCT05260684 | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US(OCEANMIST) | completed | — | 716 | PfizerINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06075615 | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Feb 7, 2025 | clinicaltrials |
| NCT05954546 | A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings | completed | — | 275 | PfizerINDUSTRY | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05238311 | Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) | no longer available | — | — | PfizerINDUSTRY | 0 | Feb 4, 2025 | clinicaltrials |
| NCT05732428 | A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China | completed | Phase 1 | 9 | PfizerINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT01121588 | Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK) | terminated | Phase 1 | 44 | PfizerINDUSTRY | 7 | Jan 23, 2025 | clinicaltrials |
| NCT04171141 | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | terminated | Phase 1 | 79 | PfizerINDUSTRY | 3 | Jan 16, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT03854227 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 54 | PfizerINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01889238 | Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | completed | Phase 2 | 118 | PfizerINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma(TTI-621-03) | terminated | Phase 2 | 76 | PfizerINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT00828919 | Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials | completed | N/A | 52 | PfizerINDUSTRY | 11 | Dec 3, 2024 | clinicaltrials |
| NCT04436120 | Treatment Resistance Following Anti-cancer Therapies | terminated | N/A | 38 | PfizerINDUSTRY | 5 | Dec 3, 2024 | clinicaltrials |
| NCT05896774 | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT01740427 | A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | completed | Phase 3 | 666 | PfizerINDUSTRY | 18 | Nov 14, 2024 | clinicaltrials |
| NCT05463952 | A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) | active not recruiting | Phase 1 | 6 | PfizerINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03672643 | Long Term Safety Observation of Crizotinib in Chinese NSCLC Population | terminated | Phase 4 | 41 | PfizerINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05567887 | A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | completed | Phase 1 | 7 | PfizerINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination(LTbR) | terminated | Phase 1 | 4 | PfizerINDUSTRY | 2 | Nov 6, 2024 | clinicaltrials |
| NCT05932290 | A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | completed | — | 514 | PfizerINDUSTRY | 1 | Oct 29, 2024 | clinicaltrials |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | completed | Phase 1 | 107 | PfizerINDUSTRY | 7 | Oct 28, 2024 | clinicaltrials |
| NCT04325698 | A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC | terminated | Phase 3 | 8 | PfizerINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05363072 | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. | completed | — | 1,112 | PfizerINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03718117 | Descriptive Observational Study ALK-2016-CPHG(ALK2016CPHG) | completed | — | 73 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05520138 | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | completed | — | 5,506 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT01210482 | Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | completed | — | 1,050 | PfizerINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials